# FoundationOne Heme

Source: https://onco.cc/drugs/foundationone-heme/  
OnCo record `foundationone-heme` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Foundation Medicine's gene test for blood cancers such as leukaemia and lymphoma, which reads RNA as well as DNA so that it finds gene fusions.

## Summary

FoundationOne Heme is Foundation Medicine's comprehensive genomic profiling test for blood cancers such as leukaemia and lymphoma. It sequences DNA from more than 400 genes and RNA from more than 250, which makes it suited to finding translocations and gene fusions, and every report gives the variant allele frequency of each finding. Foundation Medicine says its gene list includes the genes professional guidelines recommend testing in leukaemia and myelodysplastic syndromes. It accepts blood, bone marrow or a tissue biopsy, with a stated turnaround of 8 days. It is a laboratory-developed test that has not been reviewed or approved by the FDA, run in Foundation Medicine's CLIA-certified, CAP-accredited laboratories.

## Fields

- Kind: Test
- Status: established
- Last checked: 2026-11-03
- Tags: test
- Brand: FoundationOne Heme
- Modality: Genomic profiling test for blood cancers (DNA and RNA sequencing)
- Mechanism: Next-generation sequencing of DNA from more than 400 genes and RNA from more than 250 genes, from blood, bone marrow or a tissue biopsy, detecting substitutions, insertions and deletions, copy number changes and gene fusions.

## Notes

- What a result means: a finding can help confirm the type of blood cancer, estimate how it is likely to behave, or point to a targeted drug or a trial; the haematologist reads it with the bone marrow and blood results.

## Sources

- Foundation Medicine: FoundationOne Heme: https://www.foundationmedicine.com/solution/foundationone-heme

## Connected records

- drugs: [FoundationOne CDx / Liquid CDx](https://onco.cc/drugs/foundationone-cdx/)
- biomarkers: [BCR::ABL1 T315I](https://onco.cc/biomarkers/bcr-abl1-t315i/), [BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR)](https://onco.cc/biomarkers/bcr-abl1-transcript/), [FLT3-ITD (internal tandem duplication)](https://onco.cc/biomarkers/flt3-itd/), [FLT3-TKD (D835 and I836 tyrosine kinase domain mutations)](https://onco.cc/biomarkers/flt3-tkd/), [IDH1 R132 mutation](https://onco.cc/biomarkers/idh1-r132/), [IDH2 mutation (R140 and R172)](https://onco.cc/biomarkers/idh2-mutation/), [KIT D816V](https://onco.cc/biomarkers/kit-d816v/), [NPM1 mutation](https://onco.cc/biomarkers/npm1-mutation/), [TP53 mutation and del(17p)](https://onco.cc/biomarkers/tp53-del17p/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/)
- companies: [Foundation Medicine (Roche)](https://onco.cc/companies/foundation-medicine/)
- terms: [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/)

---
JSON: https://onco.cc/api/v1/entities/foundationone-heme.json